German pharmaceutical company Boehringer Ingelberg announced Tuesday that their investigational weight loss medication achieved remarkable results in a major clinical study, with participants shedding an average of 16.6% of their body weight.
The comprehensive Phase III clinical trial tracked patients for 76 weeks and found those receiving survodutide experienced substantial weight reduction compared to just 3.2% weight loss among participants who received a placebo treatment.
The study focused on adults who were either obese or overweight but did not have type 2 diabetes as a complicating factor.
The German pharmaceutical giant obtained exclusive development and marketing rights for survodutide in 2011 through an agreement with Denmark-based Zealand Pharma, which will receive royalty payments from worldwide sales of the drug.
Complete findings from the Phase III study, designated as SYNCHRONIZE-1, are scheduled to be unveiled at the American Diabetes Association’s 2026 Scientific Sessions conference, taking place June 5-8.
The medication works by copying the effects of GLP-1, an appetite-reducing hormone found in the digestive system that is also targeted by injection treatments like Novo Nordisk’s Wegovy. However, survodutide also mimics glucagon, another digestive hormone, creating a dual-action approach that researchers believe may enhance weight reduction results.
Another pharmaceutical company, Altimmune, is also working on a treatment that harnesses these same two hormone pathways.
Earlier this year, survodutide showed encouraging results in middle-stage trials for treating fatty liver disease, also called metabolic dysfunction-associated steatohepatitis or MASH.
